Results 211 to 220 of about 267,107 (334)

Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery

open access: yesAggregate, EarlyView.
This review highlights recent progress in cell membrane‐coated lipid nanoparticles (CMC‐LNPs), focusing on their design, preparation methods, functional integration, and biomedical applications. It discusses various types of LNPs and coating strategies, characterization techniques, therapeutic functions, and applications.
Moataz B. Zewail   +5 more
wiley   +1 more source

Comparative analysis of short‐term and long‐term LL‐37‐induced rosacea‐like mouse models: Histopathological features and inflammatory immune responses

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The aim of this study was to improve the long‐term LL‐37 mouse model and compare the disease manifestations and pathophysiology of short‐term and long‐term LL‐37‐induced rosacea‐like models. The results show that the long‐term LL‐37 induced mouse model provides a practical animal model for further study of the pathological mechanism of severe rosacea ...
Yiling Wu   +10 more
wiley   +1 more source

Animal models of lung cancer: Phenotypic comparison of different animal models of lung cancer and their application in the study of mechanisms

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Grafts used to construct lung cancer animal models come from various sources, primarily cell lines, patient‐derived tumor tissues, and circulating tumor cells. Based on the sources of grafts and research objectives, lung cancer animal models can be categorized into several types: chemical‐induced models, orthotopic transplantation models, heterotopic ...
Zixuan Yang   +7 more
wiley   +1 more source

Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms

open access: yesAdvanced NanoBiomed Research, EarlyView.
Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for targeted cancer treatment. Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment.
Wei Zhang   +4 more
wiley   +1 more source

Advances on Albumin‐Based Carriers for Anticancer Drug Delivery

open access: yesAdvanced NanoBiomed Research, EarlyView.
This study systematically classifies the drug delivery modes of albumin by examining the characteristics of its surface‐active groups and internal binding sites. It provides an in‐depth analysis of various drug delivery strategies and their corresponding targeting mechanisms.
Ruoli Zhou   +4 more
wiley   +1 more source

Functional Synovium‐Based 3D Models in the Context of Human Disease and Inflammation

open access: yesAdvanced NanoBiomed Research, EarlyView.
The synovium is key to joint function but is often affected by diseases like rheumatoid arthritis. Finding better treatments is challenging because current lab models do not fully mimic real tissues. New 3D technologies, like bioprinting, offer better methods to study these diseases, improve drug testing, and develop personalized treatments, bringing ...
Amelia Heslington   +3 more
wiley   +1 more source

Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.

open access: yesAmerican Journal of Pathology, 2016
Michael M. Yue   +6 more
semanticscholar   +1 more source

Review of the anatomical basis for predicting plutonium alpha particle radiation induced osteogenic cancers

open access: yesThe Anatomical Record, EarlyView.
Abstract Plutonium was discovered and first synthesized in the early 1940's. Several isotopes of plutonium are used in nuclear technologies, 238Pu for heat generation and 239Pu for energy production and weapons. Both isotopes emit alpha particles, which pose a significant radiation hazard when incorporated into the body.
Scott C. Miller
wiley   +1 more source

Home - About - Disclaimer - Privacy